Virax Biolabs Group (NASDAQ:VRAX) Downgraded by Wall Street Zen to “Sell”

Virax Biolabs Group (NASDAQ:VRAX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Virax Biolabs Group currently has a consensus rating of “Hold” and an average target price of $25.00.

Virax Biolabs Group Stock Performance

NASDAQ VRAX opened at $3.13 on Friday. The company has a fifty day moving average price of $4.44 and a 200-day moving average price of $5.60. Virax Biolabs Group has a 1 year low of $2.50 and a 1 year high of $28.50.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.